Zydus Cadila Leading Global Race For Humira Biosimilar?
This article was originally published in PharmAsia News
Executive Summary
India’s Zydus Cadila stands a bright chance of leading the heated global chase to launch a biosimilar version of adalimumab, AbbVie’s blockbuster Humira, which is also the top-selling drug in the world notching close to $11 billion last year.